Benign Prostatic Hyperplasia Treatment Device Market to Grow from USD 1.72 Billion in 2025 to USD 3.78 Billion by 2034

A benign prostatic hyperplasia (BPH) treatment device is a medical instrument designed to relieve urinary symptoms caused by prostate enlargement by reducing excess prostate tissue or widening the urethral passage

According to Straits Research, the global benign prostatic hyperplasia (BPH) treatment device market size was valued at USD 1.72 billion in 2025 and is projected to grow from USD 1.88 billion in 2026 to USD 3.78 billion by 2034, registering a CAGR of 9.14% during the forecast period. North America held the largest regional share at 35.62% in 2025, while Asia Pacific is expected to record the fastest growth at a CAGR of 11.47%. Greater use of minimally invasive procedures and advances in prostate treatment technologies are expected to support market growth.

  • Market Size 2025: USD 1.72 billion

  • Market Size 2026: USD 1.88 billion

  • CAGR (Forecast Period): 9.14%

  • Forecast Year: 2034

  • Projected Market Size: USD 3.78 billion

  • Dominant Region: North America – 35.62% share in 2025

  • Fastest Growing Region: Asia Pacific – 11.47% CAGR

Market Overview

Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland that can obstruct urine flow and cause lower urinary tract symptoms. BPH treatment devices help relieve this obstruction through tissue removal, ablation, or mechanical support. Available technologies include laser systems, transurethral resection devices, UroLift systems, radiofrequency ablation devices, and robotic waterjet aquablation systems. Hospitals, ambulatory surgical centers, and specialty clinics use these devices to provide procedural treatment for patients with varying disease severity.

Growth Drivers

  • Greater Preference for Minimally Invasive Procedures: Patients and clinicians increasingly consider procedures that can relieve urinary symptoms with shorter recovery periods and less tissue disruption. This supports the use of laser systems, prostatic urethral lift devices, and other minimally invasive technologies.

  • Higher Prevalence of Prostate Enlargement: BPH is common among older men and can lead to urinary symptoms that require medical or procedural care. The need for effective symptom relief supports the use of specialized treatment devices.

  • Advances in Surgical Technology: Improvements in laser systems, robotic platforms, and waterjet-based procedures can support precision and procedural efficiency. These developments encourage hospitals and urology centers to upgrade their treatment capabilities.

Market Challenges

  • High Device and Procedure Costs: Advanced laser and robotic systems require substantial capital investment. Procedure costs may also limit access for patients without adequate insurance coverage or reimbursement.

  • Need for Skilled Urology Professionals: Many BPH procedures require trained urologists and specialized clinical teams. Limited availability of skilled professionals can restrict adoption, particularly in smaller hospitals and emerging markets.

  • Clinical Suitability and Procedure Risks: Device selection depends on prostate size, patient health, and symptom severity. Differences in clinical outcomes and potential complications can influence physician preference and patient acceptance.

Market Opportunities

  • Expansion of Minimally Invasive Treatment Options: Urology centers can adopt devices that offer effective symptom relief with less invasive procedures. Manufacturers can generate revenue through device sales, consumables, service agreements, and training programs.

  • Growth of Robotic and Image-Guided Procedures: Hospitals seeking improved procedural precision can invest in robotic waterjet systems and advanced laser platforms. Device developers can expand through technology partnerships, clinical education, and wider access to specialized urology centers.

Segment Analysis

By device type, laser systems led the market with a 28.5% share in 2025. Their established role in prostate tissue removal and ablation, along with their use across different BPH procedures, supports their position.

By surgery type, minimally invasive surgery is expected to grow at a CAGR of 10.65% during the forecast period. Patient interest in procedures that reduce tissue disruption and recovery time supports wider use of these techniques.

By end use, hospitals held a 59.5% share in 2025. Their access to urologists, operating facilities, diagnostic services, and post-procedure care supports their leading role in device use.

Regional Analysis

North America led the market in 2025 with a share of 35.62%, supported by established urology services, access to advanced medical devices, and wider use of minimally invasive procedures. The presence of major device manufacturers and specialized treatment centers also supports regional adoption.

Asia Pacific is expected to record the fastest growth at a CAGR of 11.47%. Greater access to healthcare services, a large aging population, and wider availability of advanced urology procedures are expected to support market development. Europe remains an established market due to its hospital infrastructure and access to modern surgical technologies. Latin America and the Middle East and Africa offer opportunities as specialist urology services and device access improve.

Competitive Landscape

The market includes medical device manufacturers that offer laser systems, transurethral resection equipment, prostatic urethral lift devices, and robotic treatment platforms. Competition centers on clinical outcomes, procedural safety, device precision, ease of use, and hospital adoption. Key participants include Boston Scientific Corporation, Teleflex Incorporated, PROCEPT BioRobotics Corporation, Olympus Corporation, and Zenflow, Inc.

Recent Developments

  • March 2026: Medeon Biodesign announced that its Urocross Expander System received U.S. FDA 510(k) clearance. The minimally invasive implant is designed to relieve lower urinary tract symptoms associated with BPH.

  • March 2026: PROCEPT BioRobotics launched its HYDROS Robotic System internationally, extending the availability of its robotic waterjet technology for BPH procedures.

  • September 2026: Boston Scientific received FDA 510(k) clearance for a change to its Rezūm System, which uses water-vapor therapy to treat benign prostatic hyperplasia.

  • October 2026: Prodeon Medical began controlled commercial use of its Urocross Expander System in the United States after its first commercial procedure.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/benign-prostatic-hyperplasia-treatment-device-market

Explore the full Benign Prostatic Hyperplasia Treatment Device Market report for detailed market estimates, segment-level analysis, regional forecasts, competitive insights, and strategic developments.

Future Outlook

The market is expected to benefit from wider adoption of minimally invasive procedures and continued advances in laser, robotic, and implant-based technologies. Hospitals and specialty clinics may increase investment in devices that offer effective symptom relief and improved procedural precision. Product innovation, clinical evidence, and broader access to urology services are likely to shape future competition.

About Straits Research

Straits Research is a market intelligence and consulting firm that provides industry insights, market forecasts, and strategic research across a broad range of sectors. The company helps organizations understand market trends, assess competitive environments, and identify opportunities for business growth.


savi ssd ssd

7 Блог сообщений

Комментарии

Install Camlive!

Install the app for the best experience, instant notifications, and improved performance.